Applied Therapeutics Inc Cash Flow Conversion Efficiency
Applied Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Applied Therapeutics Inc (APLT) has a cash flow conversion efficiency ratio of 32.800x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.40 Million) by net assets ($-561.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Applied Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of Applied Therapeutics Inc from 2017 to 2024. This chart illustrates how Applied Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Applied Therapeutics Inc stock price today for real-time trading data and today's change.
Applied Therapeutics Inc Cash Flow Conversion Ratio Explained
Applied Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Applied Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Applied Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FirstGroup PLC
LSE:FGP
|
0.583x |
|
INNO-GENE SA ZY -10
F:WQ3
|
0.003x |
|
Safestore Holdings Plc
LSE:SAFE
|
0.026x |
|
COSMOS HEALTH NEW DL-01
F:V67A
|
-0.249x |
|
Bellavista Resources Ltd
AU:BVR
|
-0.067x |
|
Dome Gold Mines Ltd
AU:DME
|
-0.023x |
|
Volt Resources Ltd
AU:VRC
|
-0.038x |
|
iRobot Corporation
NASDAQ:IRBT
|
1.770x |
Annual Cash Flow Conversion Efficiency for Applied Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Applied Therapeutics Inc from 2017 to 2024. Review Applied Therapeutics Inc (APLT) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.01 Million | $-84.31 Million | -1.479x | -145.96% |
| 2023-12-31 | $-17.15 Million | $-55.17 Million | 3.218x | +116.73% |
| 2022-12-31 | $4.06 Million | $-78.09 Million | -19.230x | -1225.53% |
| 2021-12-31 | $62.54 Million | $-90.73 Million | -1.451x | -51.99% |
| 2020-12-31 | $81.94 Million | $-78.21 Million | -0.954x | +14.28% |
| 2019-12-31 | $32.61 Million | $-36.31 Million | -1.113x | -57.51% |
| 2018-12-31 | $15.82 Million | $-11.18 Million | -0.707x | -187.64% |
| 2017-12-31 | $-3.96 Million | $-3.19 Million | 0.807x | -- |
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more